MedTrace Logo

sCD163 & CD19 as Candidate Biomarkers in CIDP and MMN

NCT02271724 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 85

Last updated 2016-05-16

No results posted yet for this study

Summary

Chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN) are characterized by progressive deterioration in muscle strength, loss of sensibility, diminished or absent reflexes and impaired fine motor control. Often it is caused by demyelination which is suitable for treatment but damage to the axons may also occur especially in case of insufficient treatment.

CIDP and MMN are immune mediated neuropathies in which first choice of treatment is intravenous immunoglobulin (IVIG), although the mechanisms underlying the effect of the IVIG is not yet clarified.

The patients are diagnosed by electrophysiological examination and elevated level of protein in the cerebrospinal fluid. The diagnosis may be difficult to make due to great clinical variation and insensitive examinations methods including lack of biomarkers.

The purpose of this study is to define if patients treated with SCIG and IVIG for CIDP and MMN have higher concentrations of sCD163 and CD19 in their cerebrospinal fluid and serum compared with symptomatic control subjects and is related to disease severity. Furthermore it is to define if patients newly diagnosed with CIDP or MMN have higher levels of sCD163 and CD19, than patients treated regularly with SCIG and IVIG.

Conditions

  • Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Interventions

PROCEDURE

Lumbar puncture

Lumbar puncture for spinal fluid

PROCEDURE

Blood sample

Blood sample

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Henning Andersen, Professor · Department of Neurology, Aarhus University Hospital

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2016-11-30
Completion
2016-11-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02271724 on ClinicalTrials.gov